Skip to main content

Table 1 Unadjusted hazard ratios for death in relation to stromal ER and PR expression, allover and stratified by KRAS mutation status and sex, respectively

From: Clinical significance of stromal ER and PR expression in periampullary adenocarcinoma

  All KRAS wild-type KRAS mutated  
n (events) HR (95% CI) n (events) HR (95% CI) n (events) HR (95% CI) Pinteraction
ER status
 All
  ER- 118 (93) 1.00 40 (27) 1.00 34 (28) 1.00 0.694
  ER+ 48 (39) 0.97 (0.67–1.41) 13 (10) 1.14 (0.55–2.37) 12 (11) 0.93 (0.46–1.88) 0.757a
  p   0.865   0.721   0.841  
 Women
  ER- 49 (35) 1.00 17 (10) 1.00 14 (10) 1.00 0.874
  ER+ 35 (26) 1.05 (0.63–1.74) 8 (5) 1.09 (0.37–3.22) 8 (7) 1.35 (0.50–3.65) 0.947a
  p   0.864   0.870   0.548  
 Men
  ER- 69 (58) 1.00 23 (17) 1.00 20 (18) 1.00 0.387
  ER+ 13 (13) 1.12 (0.61–2.05) 5 (5) 1.30 (0.47–3.59) 4 (4) 0.63 (0.21–1.92) 0.516a
  p   0.723   0.613   0.420  
PR status
 All
  PR- 111 (86) 1.00 38 (24) 1.00 29 (26) 1.00 0.026
  PR+ 49 (43) 1.25 (0.87–1.81) 12 (11) 1.94 (0.94–3.98) 17 (14) 0.66 (0.34–1.27) 0.037a
  p   0.234   0.071   0.216  
 Women
  PR- 52 (36) 1.00 18 (9) 1.00 12 (11) 1.00 0.002
  PR+ 28 (24) 1.35 (0.80–2.27) 6 (6) 2.85 (1.01–8.09) 9 (6) 0.030 (0.11–0.85) 0.004a
  p   0.257   0.048   0.024b  
 Men
  PR- 59 (50) 1.00 20 (15) 1.00 17 (15) 1.00 0.678
  PR+ 21 (19) 1.23 (0.72–2.09) 6 (5) 1.32 (0.47–3.70) 8 (8) 1.70 (0.71–4.07) 0.785a
  p   0.452   0.592   0.234  
  1. aInteraction analysis including adjustment for morphological type (I-type/PB-type)
  2. bHazard ratio adjusted for morphological type 0.28 (0.10–0.80) in women